首页 > 最新文献

Scandinavian Journal of Urology最新文献

英文 中文
A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. 前列腺癌患者的合并症指数和预期寿命的比较。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-06-03 DOI: 10.2340/sju.v60.43810
Eugenio Ventimiglia, Rolf Gedeborg, Andri Wilberg Orrason, Paolo Zaurito, Hans Garmo, Pär Stattin, Marcus Westerberg

N/A.

N/A。
{"title":"A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer.","authors":"Eugenio Ventimiglia, Rolf Gedeborg, Andri Wilberg Orrason, Paolo Zaurito, Hans Garmo, Pär Stattin, Marcus Westerberg","doi":"10.2340/sju.v60.43810","DOIUrl":"https://doi.org/10.2340/sju.v60.43810","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"105-107"},"PeriodicalIF":1.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Swedish regional population-based organised prostate cancer testing: why, what and how? 瑞典地区人群有组织的前列腺癌检测:为什么,做什么,怎么做?
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-06-03 DOI: 10.2340/sju.v60.43809
Ola Bratt, Salma Tunå Butt, Charlotte Carlsson, Lisa Jelf-Eneqvist, Olof Gunnarsson, Alma Ihre, Thomas Jiborn, Anna Lantz, Heide Larsson, Helena Strömqvist, Johan Styrke, Nils-Erik Svedberg, Rebecka Arnsrud Godtman

Objective: This study aimed to describe the regional, population-based, organised prostate cancer testing (OPT) programmes that are being introduced throughout Sweden: motives, structure, target population, diagnostic algorithm, quality control, outcomes, research, and future perspectives.

Results: In 2018, the Swedish National Board of Health and Welfare renewed their recommendation against screening for prostate cancer. Despite this, regional OPT was considered motivated to (1) improve cost-effectiveness compared with unorganised testing, (2) improve equity by giving every man in the target population a chance to make an informed choice, and (3) gain diagnostic and organisational knowledge. The OPT programmes are provided as a regional public healthcare service. They are coordinated by a national working group. The final target population is all men aged 50-74 years. Regional OPT offices use a national administrative system to organise all steps from sending invitation letters to prostate biopsy according to a strict diagnostic algorithm. General practice is involved for blood draw only or not at all. Data are registered in a national register (SweOPT); an annual report is published with the regions' performance on key indicators. At the end of 2024, 16 of the 21 Swedish regions had started OPT and invited 256,000 men with an average cumulative participation rate of 43%. A consortium co-ordinates OPT-related research. A general experience is that communication and organisational matters have been more challenging than medical decisions.

Conclusions: The Swedish population-based OPT programmes provide organisational experiences, diagnostic outcomes, and research results of value for future national prostate cancer screening programmes.

目的:本研究旨在描述瑞典正在推行的区域性、以人群为基础的、有组织的前列腺癌检测(OPT)项目:动机、结构、目标人群、诊断算法、质量控制、结果、研究和未来前景。结果:2018年,瑞典国家健康和福利委员会更新了他们对前列腺癌筛查的建议。尽管如此,区域性OPT被认为是有动机的:(1)与无组织的测试相比,提高成本效益;(2)通过给目标人群中的每个人一个做出知情选择的机会来提高公平性;(3)获得诊断和组织知识。OPT方案是作为一项区域公共保健服务提供的。它们由一个国家工作组协调。最终的目标人群是所有50-74岁的男性。根据严格的诊断算法,区域OPT办公室使用国家管理系统来组织从发送邀请函到前列腺活检的所有步骤。一般做法是只抽血或根本不抽血。数据在国家登记册中登记(SweOPT);每年发布一份报告,介绍各区域在关键指标上的表现。到2024年底,瑞典21个地区中有16个地区启动了OPT,并邀请了256,000名男性,平均累计参与率为43%。一个财团负责协调opt相关的研究。一个普遍的经验是,沟通和组织问题比医疗决策更具挑战性。结论:瑞典基于人群的OPT项目为未来的国家前列腺癌筛查项目提供了有价值的组织经验、诊断结果和研究结果。
{"title":"Swedish regional population-based organised prostate cancer testing: why, what and how?","authors":"Ola Bratt, Salma Tunå Butt, Charlotte Carlsson, Lisa Jelf-Eneqvist, Olof Gunnarsson, Alma Ihre, Thomas Jiborn, Anna Lantz, Heide Larsson, Helena Strömqvist, Johan Styrke, Nils-Erik Svedberg, Rebecka Arnsrud Godtman","doi":"10.2340/sju.v60.43809","DOIUrl":"10.2340/sju.v60.43809","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to describe the regional, population-based, organised prostate cancer testing (OPT) programmes that are being introduced throughout Sweden: motives, structure, target population, diagnostic algorithm, quality control, outcomes, research, and future perspectives.</p><p><strong>Results: </strong>In 2018, the Swedish National Board of Health and Welfare renewed their recommendation against screening for prostate cancer. Despite this, regional OPT was considered motivated to (1) improve cost-effectiveness compared with unorganised testing, (2) improve equity by giving every man in the target population a chance to make an informed choice, and (3) gain diagnostic and organisational knowledge. The OPT programmes are provided as a regional public healthcare service. They are coordinated by a national working group. The final target population is all men aged 50-74 years. Regional OPT offices use a national administrative system to organise all steps from sending invitation letters to prostate biopsy according to a strict diagnostic algorithm. General practice is involved for blood draw only or not at all. Data are registered in a national register (SweOPT); an annual report is published with the regions' performance on key indicators. At the end of 2024, 16 of the 21 Swedish regions had started OPT and invited 256,000 men with an average cumulative participation rate of 43%. A consortium co-ordinates OPT-related research. A general experience is that communication and organisational matters have been more challenging than medical decisions.</p><p><strong>Conclusions: </strong>The Swedish population-based OPT programmes provide organisational experiences, diagnostic outcomes, and research results of value for future national prostate cancer screening programmes.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"97-104"},"PeriodicalIF":1.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study. 瑞典在2019冠状病毒病大流行之前、期间和之后的前列腺癌发病率。以人群为基础的研究。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-05-20 DOI: 10.2340/sju.v60.43172
Paolo Zaurito, Hans Garmo, Rolf Gedeborg, Mats Ahlberg, Andri Wilberg Orrason, Johan Styrke, David Robinson, Pär Stattin, Marcus Westerberg

N/A.

N/A。
{"title":"Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study.","authors":"Paolo Zaurito, Hans Garmo, Rolf Gedeborg, Mats Ahlberg, Andri Wilberg Orrason, Johan Styrke, David Robinson, Pär Stattin, Marcus Westerberg","doi":"10.2340/sju.v60.43172","DOIUrl":"https://doi.org/10.2340/sju.v60.43172","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"93-96"},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inferior vena cava syndrome as the initial manifestation of metastatic prostate cancer: a rare case successfully treated with endovascular stenting. 转移性前列腺癌以下腔静脉综合征为首发表现:一例血管内支架成功治疗的罕见病例。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-05-15 DOI: 10.2340/sju.v60.43708
Dimitra Akrivou, Andreas Forsvall, Angelos Katevatis, Tobias Kühme, Anna Eliasson, Magnus Wagenius
{"title":"Inferior vena cava syndrome as the initial manifestation of metastatic prostate cancer: a rare case successfully treated with endovascular stenting.","authors":"Dimitra Akrivou, Andreas Forsvall, Angelos Katevatis, Tobias Kühme, Anna Eliasson, Magnus Wagenius","doi":"10.2340/sju.v60.43708","DOIUrl":"https://doi.org/10.2340/sju.v60.43708","url":null,"abstract":"","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"90-92"},"PeriodicalIF":1.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early and late surgical complications following living donor nephrectomy. 活体供肾切除术后早期和晚期手术并发症。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-05-05 DOI: 10.2340/sju.v60.43346
Julia Dagnæs-Hansen, Gitte H Kristensen, Malene Rohrsted, Søren S Sørensen, Andreas Røder

Objective: To report early and late surgical complications following laparoscopic, open and hand-assisted laparoscopic living donor nephrectomy, including duration of sick leave, kidney function and potential risk factors for surgical complications.

Material and methods: Retrospective study on living kidney donors between September 2014 and June 2021 at Rigshopitalet, Copenhagen. Patient data included demographics, comorbidities, surgical information, and postoperative complications (early <30 days and late >30 days). Complications were graded according to Clavien Dindo (CD). Return to work and reasons for prolonged sick leave were recorded. Multivariable logistic regression to identify risk factors for early complications CD ≥ 2 and time-dependent cause specific Cox regression to identify risk factors for late complications.  Results: A total of 223 living donors were included. Early complications were observed in 22% of donors. Early complications were often mild, and the most common complications were pneumonia, wound infection, and urinary retention. Of the 201 donors available for long-term follow-up, 10% experienced a late complication, including incisional port-site hernia and chronic post-surgical pain. 18% reported a prolonged sick leave beyond the planned 6 weeks.  Conclusions: Living donor nephrectomy is associated with a low risk of serious early surgical complications although many will experience minor related complications. As surgical safety has been confirmed in several studies the focus should be on the psychoscial and long-term aspects of living kidney donation to meet donor concerns pre-donation.

目的:报告腹腔镜、开放和手助腹腔镜活体供肾切除术术后的早期和晚期手术并发症,包括病假时间、肾功能及手术并发症的潜在危险因素。材料和方法:2014年9月至2021年6月在哥本哈根Rigshopitalet对活体肾供者进行回顾性研究。患者资料包括人口统计学、合并症、手术信息和术后并发症(前30天)。根据Clavien Dindo (CD)对并发症进行分级。复工和长时间病假的原因被记录下来。多变量logistic回归识别早期并发症的危险因素,CD≥2和时间相关的病因特异性Cox回归识别晚期并发症的危险因素。结果:共纳入223例活体供体。22%的献血者出现早期并发症。早期并发症通常是轻微的,最常见的并发症是肺炎、伤口感染和尿潴留。在201名可进行长期随访的供体中,10%出现了晚期并发症,包括切口端口疝和慢性术后疼痛。18%的人报告说,他们的病假超过了计划的6周。结论:活体供肾切除术早期严重并发症的风险较低,尽管许多患者会出现轻微的相关并发症。由于手术安全性已在几项研究中得到证实,因此重点应放在活体肾脏捐赠的心理和长期方面,以满足捐赠前捐赠者的担忧。
{"title":"Early and late surgical complications following living donor nephrectomy.","authors":"Julia Dagnæs-Hansen, Gitte H Kristensen, Malene Rohrsted, Søren S Sørensen, Andreas Røder","doi":"10.2340/sju.v60.43346","DOIUrl":"https://doi.org/10.2340/sju.v60.43346","url":null,"abstract":"<p><strong>Objective: </strong>To report early and late surgical complications following laparoscopic, open and hand-assisted laparoscopic living donor nephrectomy, including duration of sick leave, kidney function and potential risk factors for surgical complications.</p><p><strong>Material and methods: </strong>Retrospective study on living kidney donors between September 2014 and June 2021 at Rigshopitalet, Copenhagen. Patient data included demographics, comorbidities, surgical information, and postoperative complications (early <30 days and late >30 days). Complications were graded according to Clavien Dindo (CD). Return to work and reasons for prolonged sick leave were recorded. Multivariable logistic regression to identify risk factors for early complications CD ≥ 2 and time-dependent cause specific Cox regression to identify risk factors for late complications.  Results: A total of 223 living donors were included. Early complications were observed in 22% of donors. Early complications were often mild, and the most common complications were pneumonia, wound infection, and urinary retention. Of the 201 donors available for long-term follow-up, 10% experienced a late complication, including incisional port-site hernia and chronic post-surgical pain. 18% reported a prolonged sick leave beyond the planned 6 weeks.  Conclusions: Living donor nephrectomy is associated with a low risk of serious early surgical complications although many will experience minor related complications. As surgical safety has been confirmed in several studies the focus should be on the psychoscial and long-term aspects of living kidney donation to meet donor concerns pre-donation.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"83-89"},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease. 瑞典尿路上皮癌国家指南:晚期和转移性疾病2024年更新
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-03-25 DOI: 10.2340/sju.v60.43236
Anders Ullén, Firas Aljabery, Pär Dahlman, Karin Falkman, Truls Gårdmark, Tomas Jerlström, Susanna Holst, Sofia Kjellström, Anna-Karin Lind, Dimitrios Papantoniou, Jonas Stenlund, Viveka Ströck, Karin Söderkvist, Helena Thulin, Elin Trägårdh, Ingrida Verbiene, Jonas Wallström, Elisabeth Öfverholm, Fredrik Liedberg

Objective: To overview and summarise the Swedish National Guidelines on Urothelial Carcinoma 2024.

Methods: A narrative review of the updated guidelines was performed, highlighting new treatment recommendations for advanced and metastasized disease.  Results: Compared to the previous guideline version, the current update includes recommendations for standardised radiological reporting when urothelial carcinomas are detected at CT-urography (CTU), to early identify locally advanced patients and accelerate the care pathway for these patients. The Swedish guidelines apply a more structured and liberal recommendation for the use of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with locally advanced urothelial carcinomas compared to the EAU-guidelines and recommend such examinations prior to transurethral resection. Improved outcomes for radical cystectomy in Sweden after centralised cystectomy care have led to a recommendation for performing more than six nephroureterectomies (NUs) per year for upper tract urothelial carcinomas (UTUC)-based associations with decreased use of invasive diagnostic modalities and better survival outcomes. Additionally, updated recommendations regarding adjuvant systemic therapies for muscle-invasive disease have been included. Whilst awaiting national regulatory approval for enfortumab vedotin/pembrolizumab, the present guideline version aligns with EAU-guidelines by endorsing cisplatin-gemcitabine-nivolumab as a new first-line treatment option in cisplatin-fit patients with unresectable or metastatic urothelial carcinoma.

Conclusions: The current version of the Swedish national guidelines on urothelial carcinoma introduces standardised reporting at CTU to facilitate early identification of advanced disease, includes recommendations for centralisation of NU for UTUC and updated recommendations for adjuvant systemic treatment of muscle-invasive disease and endorses cisplatin-gemcitabine-nivolumab as a new first-line treatment option for non-resectable locally advanced and metastatic disease.

目的:概述和总结瑞典国家尿路上皮癌指南2024。方法:对更新的指南进行叙述性回顾,重点介绍了晚期和转移性疾病的新治疗建议。结果:与之前的指南版本相比,当前的更新包括了在ct尿路造影(CTU)检测到尿路上皮癌时标准化放射报告的建议,以早期识别局部晚期患者并加快这些患者的护理途径。与eau指南相比,瑞典指南对局部晚期尿路上皮癌患者使用18f -氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描的建议更为结构化和宽松,并建议在经尿道切除术前进行此类检查。在瑞典,集中膀胱切除术治疗后根治性膀胱切除术的预后有所改善,因此推荐每年对基于上尿路上皮癌(UTUC)的患者进行6次以上肾输尿管切除术(NUs),同时减少侵入性诊断方式的使用,改善生存结果。此外,关于肌肉侵袭性疾病的辅助全身性治疗的最新建议也包括在内。在等待国家监管机构批准enfortumab vedotin/pembrolizumab的同时,目前的指南版本与eu指南一致,支持顺铂-吉西他滨-尼沃单抗作为顺铂适合患者不可切除或转移性尿路上皮癌的新的一线治疗选择。结论:当前版本的瑞典尿路上皮癌国家指南引入了CTU的标准化报告,以促进晚期疾病的早期识别,包括推荐UTUC的NU集中治疗和肌肉侵袭性疾病的辅助全身治疗的更新建议,并支持顺铂-吉西他滨-尼沃单抗作为不可切除的局部晚期和转移性疾病的新的一线治疗选择。
{"title":"Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease.","authors":"Anders Ullén, Firas Aljabery, Pär Dahlman, Karin Falkman, Truls Gårdmark, Tomas Jerlström, Susanna Holst, Sofia Kjellström, Anna-Karin Lind, Dimitrios Papantoniou, Jonas Stenlund, Viveka Ströck, Karin Söderkvist, Helena Thulin, Elin Trägårdh, Ingrida Verbiene, Jonas Wallström, Elisabeth Öfverholm, Fredrik Liedberg","doi":"10.2340/sju.v60.43236","DOIUrl":"10.2340/sju.v60.43236","url":null,"abstract":"<p><strong>Objective: </strong>To overview and summarise the Swedish National Guidelines on Urothelial Carcinoma 2024.</p><p><strong>Methods: </strong>A narrative review of the updated guidelines was performed, highlighting new treatment recommendations for advanced and metastasized disease.  Results: Compared to the previous guideline version, the current update includes recommendations for standardised radiological reporting when urothelial carcinomas are detected at CT-urography (CTU), to early identify locally advanced patients and accelerate the care pathway for these patients. The Swedish guidelines apply a more structured and liberal recommendation for the use of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with locally advanced urothelial carcinomas compared to the EAU-guidelines and recommend such examinations prior to transurethral resection. Improved outcomes for radical cystectomy in Sweden after centralised cystectomy care have led to a recommendation for performing more than six nephroureterectomies (NUs) per year for upper tract urothelial carcinomas (UTUC)-based associations with decreased use of invasive diagnostic modalities and better survival outcomes. Additionally, updated recommendations regarding adjuvant systemic therapies for muscle-invasive disease have been included. Whilst awaiting national regulatory approval for enfortumab vedotin/pembrolizumab, the present guideline version aligns with EAU-guidelines by endorsing cisplatin-gemcitabine-nivolumab as a new first-line treatment option in cisplatin-fit patients with unresectable or metastatic urothelial carcinoma.</p><p><strong>Conclusions: </strong>The current version of the Swedish national guidelines on urothelial carcinoma introduces standardised reporting at CTU to facilitate early identification of advanced disease, includes recommendations for centralisation of NU for UTUC and updated recommendations for adjuvant systemic treatment of muscle-invasive disease and endorses cisplatin-gemcitabine-nivolumab as a new first-line treatment option for non-resectable locally advanced and metastatic disease.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"76-82"},"PeriodicalIF":1.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unexpected Liver Metastasis Three Years after Nephrectomy for Renal Oncocytoma: A Case-report and Review of Literature. 肾肿瘤细胞瘤切除术后3年意外肝转移:1例报告及文献回顾。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-03-20 DOI: 10.2340/sju.v60.43205
Pekka Lammi, Anna Junttila, Essi Ikonen, Arto Salonen, Olli Lahtinen, Antti Kivivuori

N/A.

N/A。
{"title":"Unexpected Liver Metastasis Three Years after Nephrectomy for Renal Oncocytoma: A Case-report and Review of Literature.","authors":"Pekka Lammi, Anna Junttila, Essi Ikonen, Arto Salonen, Olli Lahtinen, Antti Kivivuori","doi":"10.2340/sju.v60.43205","DOIUrl":"10.2340/sju.v60.43205","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"73-75"},"PeriodicalIF":1.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare costs in relation to increased use of preoperative renal tumour biopsies. 与术前肾肿瘤活检使用增加有关的医疗费用。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-03-13 DOI: 10.2340/sju.v60.43194
Agnes Lind, Bassam Mazin Hashim, Matilda Hagman, Susanna Holst, Andreas Karlsson Rosenblad, Börje Ljungberg, Per-Olof Lundgren, Sven Lundstam, Camilla Nystrand, Fanny Goude, Tobias Lauritsen

Objective: To analyse the budget impact of adopting routine renal tumour biopsy (RTB) prior to decision on surgical treatment for clinical T1 renal tumours in Sweden.

Material and methods: This study used data from the National Swedish Kidney Cancer Register including 4,109 T1N0M0 renal tumours surgically treated during the years 2018-2022. We modelled a gradual increase in the proportion of preoperative RTBs over a five-year period, from 15.6 % of surgically removed clinical T1N0M0 renal tumors up to 90 % preoperative RTBs by 2029. Average costs per patient were calculated primarily using the Swedish cost-per-patient database. The analyses were stratified by tumour diameter: ≤40 mm (cT1a) and 41-70 mm (cT1b). The proportion of patients with benign RTB, complication rate and false negative RTBs was estimated from register data and previous research. A healthcare perspective was used and accounted for costs related to biopsy, surgery, follow-up of benign RTBs, complications and re-biopsy in cases of inconclusive RTBs.

Results: For cT1a, increasing preoperative RTBs to 90% of the study population reduced the net annual costs by €691,620, whilst for cT1b, costs increased by €67,630. Overall, an increase in preoperative RTBs to 90% of all patients with cT1 renal tumours was projected to reduce spending by €623,990 annually.

Conclusions: The budget impact analysis of routine preoperative RTBs in suspected renal cell carcinoma indicates net healthcare cost savings in cT1a and potentially for all cT1 tumours.

目的分析瑞典临床T1肾肿瘤在决定手术治疗前采用常规肾肿瘤活检(RTB)对预算的影响:本研究使用了瑞典国家肾癌登记处的数据,包括2018-2022年间接受手术治疗的4109例T1N0M0肾肿瘤。我们模拟了术前 RTB 的比例在五年内逐渐增加的情况,从手术切除临床 T1N0M0 肾肿瘤的 15.6% 增加到 2029 年术前 RTB 的 90%。每名患者的平均成本主要通过瑞典每名患者成本数据库计算得出。分析按肿瘤直径分层:≤40 毫米(cT1a)和 41-70 毫米(cT1b)。良性 RTB 患者比例、并发症发生率和假阴性 RTB 是根据登记数据和以往研究估算得出的。研究采用了医疗保健视角,计算了活检、手术、良性 RTB 随访、并发症和 RTB 未确诊情况下重新活检的相关费用:对于 cT1a,将术前 RTB 的比例提高到 90%,每年的净成本就减少了 691,620 欧元,而对于 cT1b,成本则增加了 67,630 欧元。总体而言,将所有cT1肾肿瘤患者的术前RTB比例提高至90%,预计每年可减少支出623,990欧元:对疑似肾细胞癌进行常规术前 RTB 的预算影响分析表明,cT1a 可节省净医疗成本,所有 cT1 肿瘤也可节省净医疗成本。
{"title":"Healthcare costs in relation to increased use of preoperative renal tumour biopsies.","authors":"Agnes Lind, Bassam Mazin Hashim, Matilda Hagman, Susanna Holst, Andreas Karlsson Rosenblad, Börje Ljungberg, Per-Olof Lundgren, Sven Lundstam, Camilla Nystrand, Fanny Goude, Tobias Lauritsen","doi":"10.2340/sju.v60.43194","DOIUrl":"10.2340/sju.v60.43194","url":null,"abstract":"<p><strong>Objective: </strong>To analyse the budget impact of adopting routine renal tumour biopsy (RTB) prior to decision on surgical treatment for clinical T1 renal tumours in Sweden.</p><p><strong>Material and methods: </strong>This study used data from the National Swedish Kidney Cancer Register including 4,109 T1N0M0 renal tumours surgically treated during the years 2018-2022. We modelled a gradual increase in the proportion of preoperative RTBs over a five-year period, from 15.6 % of surgically removed clinical T1N0M0 renal tumors up to 90 % preoperative RTBs by 2029. Average costs per patient were calculated primarily using the Swedish cost-per-patient database. The analyses were stratified by tumour diameter: ≤40 mm (cT1a) and 41-70 mm (cT1b). The proportion of patients with benign RTB, complication rate and false negative RTBs was estimated from register data and previous research. A healthcare perspective was used and accounted for costs related to biopsy, surgery, follow-up of benign RTBs, complications and re-biopsy in cases of inconclusive RTBs.</p><p><strong>Results: </strong>For cT1a, increasing preoperative RTBs to 90% of the study population reduced the net annual costs by €691,620, whilst for cT1b, costs increased by €67,630. Overall, an increase in preoperative RTBs to 90% of all patients with cT1 renal tumours was projected to reduce spending by €623,990 annually.</p><p><strong>Conclusions: </strong>The budget impact analysis of routine preoperative RTBs in suspected renal cell carcinoma indicates net healthcare cost savings in cT1a and potentially for all cT1 tumours.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"66-72"},"PeriodicalIF":1.4,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quadratus lumborum block is feasible alternative to epidural block for postoperative analgesia after open radical cystectomy: surgical and oncological outcomes of a randomised clinical trial. 腰方肌阻滞是开放式根治性膀胱切除术后硬膜外阻滞的可行替代方案:一项随机临床试验的外科和肿瘤学结果
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-03-13 DOI: 10.2340/sju.v60.43105
Erik Veskimäe, Andrus Korgvee, Heini Huhtala, Heikki Koskinen, Maija-Liisa Kalliomaki, Teuvo Tammela, Eija Junttila

Objective: The current lack of standardised perioperative pain management protocols for open radical cystectomy (ORC) underscores the need for alternative approaches to the longstanding tradition of epidural block. The aim of this study was to assess the impact of bilateral single injection quadratum lumborum block (QLB) on patients' recovery and complication rates compared with epidural analgesia after ORC in a single-centre, randomised, parallel-group trial including adult patients with bladder cancer.

Material and methods: Consecutive ORC patients were randomly allocated into QLB and the epidural group. The primary endpoint of this study was related to opioid consumption, and the results have been published earlier. This report focuses on secondary outcomes.

Results: This study included a total of 41 patients, with 20 patients in the QLB group and 21 patients in the epidural group. Finally, 39 patients were included in the analysis.  There was a trend for more frequent need for postoperative norepinephrine and fluid support in the epidural group but without statistical significance. Postoperative complication rate was similar. Two patients in the epidural group compared to none in the QLB group were rehospitalised within 30 and 90 days. Mortality rate within 90 days was higher in the epidural group (4 vs. 0 patients, P = 0.064).

Conclusions: In this trial, there were no significant differences in surgical and oncological outcomes after ORC when QLB is compared with epidural block for postoperative analgesia.  Trial registration: ClinicalTrials.gov Identifier: NCT03328988.

目的:开放式根治性膀胱切除术(ORC)目前缺乏标准化的围手术期疼痛管理方案,这表明需要替代硬膜外阻滞的传统方法。本研究的目的是在一项包括膀胱癌成年患者的单中心、随机、平行组试验中,评估双侧单次注射腰方阻滞(QLB)对ORC后患者恢复和并发症发生率的影响,并与硬膜外镇痛进行比较。材料与方法:将连续ORC患者随机分为QLB组和硬膜外组。本研究的主要终点与阿片类药物消费有关,研究结果已在较早前发表。本报告侧重于次要结果。结果:本研究共纳入41例患者,QLB组20例,硬膜外组21例。最终,39例患者被纳入分析。硬膜外组术后更频繁地需要去甲肾上腺素和液体支持,但无统计学意义。术后并发症发生率相似。硬膜外组有2例患者在30天和90天内再次住院,而QLB组没有。硬膜外组90天内死亡率较高(4例vs. 0例,P = 0.064)。结论:在本试验中,与硬膜外阻滞相比,QLB在ORC术后的手术和肿瘤结果没有显著差异。试验注册:ClinicalTrials.gov标识符:NCT03328988。
{"title":"Quadratus lumborum block is feasible alternative to epidural block for postoperative analgesia after open radical cystectomy: surgical and oncological outcomes of a randomised clinical trial.","authors":"Erik Veskimäe, Andrus Korgvee, Heini Huhtala, Heikki Koskinen, Maija-Liisa Kalliomaki, Teuvo Tammela, Eija Junttila","doi":"10.2340/sju.v60.43105","DOIUrl":"10.2340/sju.v60.43105","url":null,"abstract":"<p><strong>Objective: </strong>The current lack of standardised perioperative pain management protocols for open radical cystectomy (ORC) underscores the need for alternative approaches to the longstanding tradition of epidural block. The aim of this study was to assess the impact of bilateral single injection quadratum lumborum block (QLB) on patients' recovery and complication rates compared with epidural analgesia after ORC in a single-centre, randomised, parallel-group trial including adult patients with bladder cancer.</p><p><strong>Material and methods: </strong>Consecutive ORC patients were randomly allocated into QLB and the epidural group. The primary endpoint of this study was related to opioid consumption, and the results have been published earlier. This report focuses on secondary outcomes.</p><p><strong>Results: </strong>This study included a total of 41 patients, with 20 patients in the QLB group and 21 patients in the epidural group. Finally, 39 patients were included in the analysis.  There was a trend for more frequent need for postoperative norepinephrine and fluid support in the epidural group but without statistical significance. Postoperative complication rate was similar. Two patients in the epidural group compared to none in the QLB group were rehospitalised within 30 and 90 days. Mortality rate within 90 days was higher in the epidural group (4 vs. 0 patients, P = 0.064).</p><p><strong>Conclusions: </strong>In this trial, there were no significant differences in surgical and oncological outcomes after ORC when QLB is compared with epidural block for postoperative analgesia.  Trial registration: ClinicalTrials.gov Identifier: NCT03328988.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"59-65"},"PeriodicalIF":1.4,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based study. 在公开报告的同时,提高了对前列腺癌指南的依从性。全国人口为基础的研究。
IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY Pub Date : 2025-02-27 DOI: 10.2340/sju.v60.43107
Andri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, Rolf Gedeborg, Johan Styrke, Marcus Westerberg

Background: Swedish national guidelines provide evidence-based recommendations for standard of care; however, little is known about adherence to them. The aim of this study was to assess adherence to management guidelines for prostate cancer (PCa).

Materials and methods: Data in the National Prostate Cancer Register (NPCR), that includes 98% of all incident PCa cases in Sweden, were used to analyse adherence to national PCa guidelines for men diagnosed between 2010 and 2023. A selection of quality indicators displayed on the public web page of NPCR were assessed.

Results: Active surveillance in men with low-risk PCa and an estimated life expectancy >10 years increased from 44% in 2010 to 88% in 2023. Radical treatment for men with localised high-risk PCa and life expectancy >10 years increased from 60% in 2010 to 86% in 2023 and for men with locally advanced PCa and life expectancy >5 years from 37% in 2010 to 64% in 2023. The proportion of radical prostatectomies for low- or intermediate-risk PCa performed with nerve-sparing technique increased from 61% in 2015 to 87% in 2023. Use of adjuvant androgen deprivation therapy after radiotherapy for men with high-risk or locally advanced PCa increased five-fold from 14% in 2010 to 73% in 2022.

Conclusion: Adherence to recommendations in national guidelines improved in Sweden between 2010 and 2023. Public, open reporting of NPCR data on adherence to guidelines down to department level is likely to have contributed to these improvements.

背景:瑞典国家指南为标准护理提供循证建议;然而,人们对它们的遵守情况知之甚少。本研究的目的是评估前列腺癌(PCa)治疗指南的依从性。材料和方法:国家前列腺癌登记处(NPCR)的数据,包括瑞典98%的PCa病例,用于分析2010年至2023年诊断的男性对国家PCa指南的遵守情况。对NPCR公共网页上显示的一些质量指标进行了评估。结果:低风险前列腺癌男性的主动监测和预期寿命从2010年的44%增加到2023年的88%。局部高危前列腺癌患者的根治性治疗和预期寿命从2010年的60%增加到2023年的86%,局部晚期前列腺癌患者的预期寿命从2010年的37%增加到2023年的64%。低或中危PCa的根治性前列腺切除术采用神经保留技术的比例从2015年的61%上升到2023年的87%。高风险或局部晚期前列腺癌患者放疗后辅助雄激素剥夺治疗的使用增加了5倍,从2010年的14%增加到2022年的73%。结论:2010年至2023年间,瑞典对国家指南建议的依从性有所提高。公开、公开地报告各部门对指导方针的遵守情况的NPCR数据可能有助于这些改进。
{"title":"Improved adherence to prostate cancer guidelines concomitant with public reporting. Nationwide population-based study.","authors":"Andri Wilberg Orrason, Pietro Scilipoti, Hans Garmo, Rolf Gedeborg, Johan Styrke, Marcus Westerberg","doi":"10.2340/sju.v60.43107","DOIUrl":"10.2340/sju.v60.43107","url":null,"abstract":"<p><strong>Background: </strong>Swedish national guidelines provide evidence-based recommendations for standard of care; however, little is known about adherence to them. The aim of this study was to assess adherence to management guidelines for prostate cancer (PCa).</p><p><strong>Materials and methods: </strong>Data in the National Prostate Cancer Register (NPCR), that includes 98% of all incident PCa cases in Sweden, were used to analyse adherence to national PCa guidelines for men diagnosed between 2010 and 2023. A selection of quality indicators displayed on the public web page of NPCR were assessed.</p><p><strong>Results: </strong>Active surveillance in men with low-risk PCa and an estimated life expectancy >10 years increased from 44% in 2010 to 88% in 2023. Radical treatment for men with localised high-risk PCa and life expectancy >10 years increased from 60% in 2010 to 86% in 2023 and for men with locally advanced PCa and life expectancy >5 years from 37% in 2010 to 64% in 2023. The proportion of radical prostatectomies for low- or intermediate-risk PCa performed with nerve-sparing technique increased from 61% in 2015 to 87% in 2023. Use of adjuvant androgen deprivation therapy after radiotherapy for men with high-risk or locally advanced PCa increased five-fold from 14% in 2010 to 73% in 2022.</p><p><strong>Conclusion: </strong>Adherence to recommendations in national guidelines improved in Sweden between 2010 and 2023. Public, open reporting of NPCR data on adherence to guidelines down to department level is likely to have contributed to these improvements.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"50-58"},"PeriodicalIF":1.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1